CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Celularity Inc
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Oct 20, 2026
$1.16−0.09 (-7.20%)
Close on Oct 19, 2026
- Market cap
- $35.15M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.82 (−41.41%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Celularity Inc saw revenue fall 62.8% to $18.97M over the twelve months to Mar 31, 2026.
Revenue
$18.97M
-62.8% vs. a year earlier
Operating income
-$60.96M
TTM Q1 2026
EPS, diluted
-$2.74
TTM Q1 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Mar 31, 2026
Valuation
- Market cap
- $35.15M
- P/E ratio
- –
- Price to sales
- 1.85
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $18.97M
- Net income
- -$71.09M
- EPS, diluted
- -$2.74
- Book value per share
- -$1.16
- Diluted shares
- 30M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$18.97M-62.8% YoY
Gross profit
$998.00K-97.1% YoY
Operating income
-$60.96M
Net income
-$71.09M
EPS, diluted
-$2.74
Free cash flow
–
Reported periodTrailing twelve months